Juan Bernal, MD
Interventional Cardiology · Birmingham, ALNPI 1003007980
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,666 of the $10,530 with a category attached, or 72.8%. 40 manufacturers reported payments, led by Abbott at 28.0% of the total.
Across 389 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Ancora Heart, Inc.$2K
- Novartis$1K
- Edwards Lifesciences$720
- Inari Medical, Inc.$588
- Johnson & Johnson$384
- plus $3K from 34 others
What the payments were for
- Travel & lodging$2,84127%
- Food & beverage$7,66673%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 95 | $2,945 |
| Ancora Heart, Inc. | 5 | $1,936 |
| Novartis | 95 | $1,149 |
| Edwards Lifesciences | 13 | $720 |
| Inari Medical, Inc. | 19 | $588 |
| Johnson & Johnson | 31 | $384 |
| Abiomed | 5 | $297 |
| Celonova Biosciences, Inc. | 1 | $296 |
| Sanofi-aventis U.S. LLC | 14 | $225 |
| Actelion Pharmaceuticals US, Inc. | 14 | $216 |
| Amgen | 14 | $175 |
| Boston Scientific | 9 | $157 |
| Pfizer | 9 | $144 |
| W. L. Gore & Associates, Inc. | 5 | $124 |
| Cvrx, Inc. | 1 | $116 |
| Boehringer Ingelheim | 7 | $110 |
| Irhythm Technologies, Inc. | 6 | $105 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| Esperion Therapeutics, Inc. | 4 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $77 |
| Biosense Webster, Inc. | 1 | $76 |
| Novo Nordisk | 4 | $74 |
| AstraZeneca | 5 | $64 |
| Medtronic | 3 | $63 |
| Bayer | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $28 |
| Philips North America LLC | 1 | $24 |
| CSL Behring | 1 | $23 |
| Livanova USA, Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Medicomp Inc | 1 | $15 |
| Pulmonx Corporation | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AccuCinch$1,886
- TRICLIP$1,156
- MitraClip System$411
- MitraClip$368
- Impella$237
- FlowTriever$151
- ClotTriever$151
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$130
- SAPIEN 3 Ultra RESILIA$122
- Barostim Neo System$116
- FLOWTRIEVER CATHETER, S$106
- CT THROMBECTOMY SYSTEM KIT$106
How this compares
$10,530 in reported general payments places this provider in the 65th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $405,416 |
| EntrestoSacubitril/Valsartan | 187 | $178,375 |
| XareltoRivaroxaban | 126 | $105,757 |
| Repatha SureclickEvolocumab | 142 | $98,721 |
| JardianceEmpagliflozin | 92 | $85,275 |
| MultaqDronedarone Hcl | 65 | $57,984 |
| FarxigaDapagliflozin Propanediol | 49 | $30,006 |
| Praluent PenAlirocumab | 30 | $18,575 |
| WegovySemaglutide | 11 | $14,206 |
| BrilintaTicagrelor | 18 | $11,432 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,600 |
| Metoprolol Succinate | 545 | $8,541 |
| Ranolazine ErRanolazine | 96 | $8,240 |
| Repatha SyringeEvolocumab | 13 | $6,543 |
| Sildenafil Citrate | 18 | $6,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $144 | $405,416468 claims |
| NovartisEntresto | $1,149 | $178,375187 claims |
| Johnson & JohnsonXarelto | $384 | $105,757126 claims |
| Boehringer IngelheimJardiance | $110 | $85,27592 claims |
| Sanofi-aventis U.S. LLCMultaq | $225 | $57,98465 claims |
| AstraZenecaFarxiga, Brilinta | $64 | $41,43867 claims |
| Novo NordiskWegovy | $74 | $14,20611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.